Liza C. Villaruz

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 21 papers. Top paper: “Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial”.

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00658-6

N/A

4.8DataRank · unranked

234 citations

Anita Giobbie‐Hurder, Srinika Ranasinghe, Katrina Kao, Ana Lako, Junko Tsuji +32 more

Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer

JAMA Oncology(2023)10.1001/jamaoncol.2023.4025

N/A

1.1DataRank · unranked

48 citations

Zhonglin Hao, Liza C. Villaruz, Jun Zhang, Jimmy Ruiz, W. Jeffrey Petty +33 more

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature Medicine(2020)10.1038/s41591-019-0716-8

N/A

0.898DataRank · unranked

397 citations

Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon +16 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084

N/A

0.574DataRank · unranked

45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

Lung Cancer(2024)10.1016/j.lungcan.2024.107928

N/A

0.434DataRank · unranked

17 citations

Jun Vivien Yin, Penelope A. Bradbury, David J. Kwiatkowski, Shiven B. Patel, Lyudmila Bazhenova +24 more

NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3012

N/A

0.396DataRank · unranked

13 citations

Karen Kelly, Saiama N. Waqar, Elizabeth J. Davis, Geoffrey I. Shapiro, Patricia LoRusso +7 more

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9024

N/A

0.360DataRank · unranked

10 citations

Mary W. Redman, Paul Wheatley‐Price, Bryan A. Faller, Liza C. Villaruz, Larry Corum +10 more

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad003

N/A

0.330DataRank · unranked

8 citations

Qian Lu, Mary W. Redman, Susan S. Tavernier, Lori M. Minasian, Ellen V. Sigal +17 more

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

The Oncologist(2025)10.1093/oncolo/oyaf362

N/A

0.307DataRank · unranked

6 citations

Mark Jelinek, Arjun Singh, Brian R. Isett, Erica S. Myers, Steven J. Mullett +23 more

Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1591

N/A

0.292DataRank · unranked

6 citations

Gilberto Lopes, T. Jeroen N. Hiltermann, Ramaswamy Govindan, Liza C. Villaruz, Emiliano Calvo +19 more

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

medRxiv(2025)10.1101/2025.07.19.25331848

N/A

0.279DataRank · unranked

5 citations

Mark Jelinek, Arjun Singh, Brian R. Isett, Erica S. Myers, Steven J. Mullett +23 more

Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04778-5

N/A

0.258DataRank · unranked

4 citations

Shivaani Kummar, Larry Rubinstein, Deborah Wilsker, Nancy Young Moore, Murielle Hogu +16 more

A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9060

N/A

0.208DataRank · unranked

3 citations

Mary W. Redman, Jennifer M. Suga, Tareq Al Baghdadi, John L. Villano, Sarah B. Goldberg +6 more

Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)

The Oncologist(2025)10.1093/oncolo/oyaf373

N/A

0.109DataRank · unranked

1 citations

Benjamin Schluger, Hong Wang, James Ohr, Daniel P. Petro, Alexander D. Fuld +10 more

Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9055

N/A

0.104DataRank · unranked

1 citations

Paul Frankel, Jonathan W. Riess, Anthony B. El-Khoueiry, Liza C. Villaruz, Stephen Leong +5 more

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9075

N/A

0.104DataRank · unranked

1 citations

Mary W. Redman, Konstantin H. Dragnev, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi +7 more

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps8603

N/A

0.104DataRank · unranked

1 citations

Austin W. Goodrich, Nathan R. Foster, Panos Savvides, Liza C. Villaruz, Patrick M. Forde +12 more

Phase I study of entinostat (Ent), atezolizumab (A), carboplatin (C), and etoposide (E) in previously untreated extensive-stage small cell lung cancer (ES-SCLC), ETCTN 10399.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e20606

N/A

0.104DataRank · unranked

1 citations

Richard Piekarz, Liza C. Villaruz, John C. Rhee, W. Victoria Lai, Bethany J. Horton +7 more

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps8598

N/A

0.104DataRank · unranked

1 citations

Austin W. Goodrich, Nathan R. Foster, Vinicius Ernani, Patrick M. Forde, Liza C. Villaruz +12 more

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04844-y

N/A

0.104DataRank · unranked

1 citations

Shivaani Kummar, Larry Rubinstein, Jennifer Zlott, Geraldine O’Sullivan Coyne, Vincent Chung +17 more

Tumor cell p38 inhibition to overcome immunotherapy resistance

Research Square(2023)10.21203/rs.3.rs-3183496/v1

N/A

0DataRank · unranked

5 citations

Rebekah Dadey, Ryan C. Augustin, Sarah Newman, Krishna B. Singh, Rose Doerfler +26 more